Dose-related effects of doxazosin on plasma lipids and aortic fatty streak formation in the hypercholesterolemic hamster model.
Doxazosin, an alpha 1-adrenergic inhibitor, has been shown to decrease hypertension and plasma lipids, especially total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C), thus reducing certain risk factors associated with increased incidence of cardiovascular disease. One preliminary report indicated that the decrease in LDL-C in hypercholesterolemic hamsters treated with doxazosin was associated with a reduction in fatty streak formation. However, since the effects of doxazosin on plasma lipids, aortic fatty streak development, or the relationship between the two have not been studied in a dose-dependent manner, these effects were further investigated over varying doses of doxazosin (0, 1, 5, 10, and 20 mg/kg body wt/day) during a 10-week period. Doxazosin administration was associated with a dose-dependent decrease in LDL-C of 2%, 29%, 52%, and 60%, whereas the degree of fatty streak formation was reduced 11%, 45%, 76%, and 92% compared with controls, with the first statistically significant decrease for both parameters at the 10 mg/kg dose. Significant correlations between LDL-C concentrations and fatty streak area suggest that doxazosin altered aortic lipid infiltration primarily by its effect on plasma lipids. However, the 20 mg/kg dose of doxazosin significantly decreased lesion area compared with the 10 mg/kg dose without a further effect on plasma lipid concentrations. Three animals at these higher doses demonstrated no stainable lipid inclusions while maintaining plasma lipid values similar to their cohorts. These exceptions to the lipid-lesion relationship raise the possibility of additional effects of doxazosin, which may occur independent of or in concert with lipoprotein cholesterol lowering, on lesion formation.
Foxall
T L
TL
Department of Animal and Nutritional Sciences, University of New Hampshire, Durham.
Shwaery
G T
GT
Stucchi
A F
AF
Nicolosi
R J
RJ
Wong
S S
SS
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D001018:Aortic Diseases / Q000209:etiology* / Q000473:pathology; D001161:Arteriosclerosis / Q000209:etiology* / Q000473:pathology; D006224:Cricetinae; D004305:Dose-Response Relationship, Drug; D017292:Doxazosin; D006937:Hypercholesterolemia / Q000097:blood / Q000150:complications*; D008055:Lipids / Q000097:blood*; D008297:Male; D008647:Mesocricetus; D011224:Prazosin / Q000031:analogs & derivatives* / Q000494:pharmacology
D000317:Adrenergic alpha-Antagonists; D008055:Lipids; D017292:Doxazosin; D011224:Prazosin